Luminal Androgen Receptor (LAR) Subtype of Triple-negative Breast Cancer: Molecular, Morphological, and Clinical Features

Overview

Journal J Zhejiang Univ Sci B

Specialties Biology
General Medicine

Date 2022 Aug 11

PMID 35953756

Authors

Sergey Vtorushin

Anastasia Dulesova

Nadezhda Krakhmal

Affiliations

Soon will be listed here.

Abstract

According to the classification presented by Lehmann BD (2016), triple-negative breast cancer (TNBC) is a heterogeneous group of malignant tumors with four specific subtypes: basal-like (subtype 1 and subtype 2), mesenchymal, and luminal androgen receptor (LAR) subtypes. The basal-like subtypes of carcinomas predominate in this group, accounting for up to 80% of all cases. Despite the significantly lower proportions of mesenchymal and LAR variants in the group of breast carcinomas with a TNBC profile, such tumors are characterized by aggressive biological behavior. To this end, the LAR subtype is of particular interest, since the literature on such tumors presents different and even contradictory data concerning the disease course and prognosis. This review is devoted to the analysis of the relevant literature, reflecting the main results of studies on the molecular properties and clinical features of the disease course of LAR-type TNBC carcinomas.

Citing Articles

LncRNA-MALAT1 promotes triple-negative breast cancer progression and function as ceRNA to target REEP5 by sponging miR-106a-5p.

Yang Q, Fu Y, Feng W, Mao J, Xu N, Liu Q Eur J Med Res. 2025; 30(1):159.

PMID: 40059235 PMC: 11892299. DOI: 10.1186/s40001-025-02420-x.

Classifications of triple-negative breast cancer: insights and current therapeutic approaches.

Chen Z, Liu Y, Lyu M, Chan C, Sun M, Yang X Cell Biosci. 2025; 15(1):13.

PMID: 39893480 PMC: 11787746. DOI: 10.1186/s13578-025-01359-0.

Single-cell transcriptional atlas of human breast cancers and model systems.

Altman J, Olex A, Zboril E, Walker C, Boyd D, Myrick R Clin Transl Med. 2024; 14(10):e70044.

PMID: 39417215 PMC: 11483560. DOI: 10.1002/ctm2.70044.

Roles of lncRNA in the diagnosis and prognosis of triple-negative breast cancer.

Yang Q, Fu Y, Wang J, Yang H, Zhang X J Zhejiang Univ Sci B. 2023; 24(12):1123-1140.

PMID: 38057269 PMC: 10710915. DOI: 10.1631/jzus.B2300067.

Advantages of contrast-enhanced ultrasound in the localization and diagnostics of sentinel lymph nodes in breast cancer.

Yang Q, Fu Y, Wang J, Yang H, Zhang X J Zhejiang Univ Sci B. 2023; 24(11):985-997.

PMID: 37961801 PMC: 10646391. DOI: 10.1631/jzus.B2300019.

References

Kensler K, Regan M, Heng Y, Baker G, Pyle M, Schnitt S . Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. Breast Cancer Res. 2019; 21(1):30. PMC: 6387478. DOI: 10.1186/s13058-019-1118-z. View

Honma N, Ogata H, Yamada A, Matsuda Y, Kontani K, Miyashita M . Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women. Hum Pathol. 2021; 111:10-20. DOI: 10.1016/j.humpath.2021.01.005. View

Xu M, Yuan Y, Yan P, Jiang J, Ma P, Niu X . Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis. Clin Breast Cancer. 2020; 20(4):e385-e396. DOI: 10.1016/j.clbc.2020.01.002. View

Pareja F, Geyer F, Marchio C, Burke K, Weigelt B, Reis-Filho J . Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer. 2017; 2:16036. PMC: 5515338. DOI: 10.1038/npjbcancer.2016.36. View

Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G . Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer. 2020; 6:54. PMC: 7568552. DOI: 10.1038/s41523-020-00197-2. View

Liu Y, Jiang Y, Xu X, Yu K, Jin X, Hu X . Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res. 2016; 18(1):33. PMC: 4791797. DOI: 10.1186/s13058-016-0690-8. View

Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marme F . Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer. 2016; 16(1):734. PMC: 5024419. DOI: 10.1186/s12885-016-2766-3. View

Wang C, Pan B, Zhu H, Zhou Y, Mao F, Lin Y . Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis. Oncotarget. 2016; 7(29):46482-46491. PMC: 5216811. DOI: 10.18632/oncotarget.10208. View

Barton V, Christenson J, Gordon M, Greene L, Rogers T, Butterfield K . Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. Cancer Res. 2017; 77(13):3455-3466. PMC: 5505342. DOI: 10.1158/0008-5472.CAN-16-3240. View

10.

Traina T, Miller K, Yardley D, Eakle J, Schwartzberg L, OShaughnessy J . Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018; 36(9):884-890. PMC: 5858523. DOI: 10.1200/JCO.2016.71.3495. View

11.

Hill B, Sarnella A, Capasso D, Comegna D, Del Gatto A, Gramanzini M . Therapeutic Potential of a Novel αβ₃ Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type. Cancers (Basel). 2019; 11(2). PMC: 6406933. DOI: 10.3390/cancers11020139. View

12.

Li S, Li X, Yang S, Pi H, Li Z, Yao P . Proteomic Landscape of Exosomes Reveals the Functional Contributions of CD151 in Triple-Negative Breast Cancer. Mol Cell Proteomics. 2021; 20:100121. PMC: 8379346. DOI: 10.1016/j.mcpro.2021.100121. View

13.

Chalakur-Ramireddy N, Pakala S . Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer. Biosci Rep. 2018; 38(1). PMC: 5789156. DOI: 10.1042/BSR20171357. View

14.

Jiang Y, Ma D, Suo C, Shi J, Xue M, Hu X . Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019; 35(3):428-440.e5. DOI: 10.1016/j.ccell.2019.02.001. View

15.

Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L . Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers. Sci Rep. 2017; 7:46659. PMC: 5397976. DOI: 10.1038/srep46659. View

16.

Li D, Lai W, Wang Q, Xiang Z, Nan X, Yang X . CD151 enrichment in exosomes of luminal androgen receptor breast cancer cell line contributes to cell invasion. Biochimie. 2021; 189:65-75. DOI: 10.1016/j.biochi.2021.06.007. View

17.

Lehmann B, Jovanovic B, Chen X, Estrada M, Johnson K, Shyr Y . Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11(6):e0157368. PMC: 4911051. DOI: 10.1371/journal.pone.0157368. View

18.

Burstein M, Tsimelzon A, Poage G, Covington K, Contreras A, Fuqua S . Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2014; 21(7):1688-98. PMC: 4362882. DOI: 10.1158/1078-0432.CCR-14-0432. View

19.

Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A . A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol. 2016; 27(5):812-8. DOI: 10.1093/annonc/mdw067. View

20.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View